Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

SPONSORED – Neuropathy is becoming a bigger problem for more people than ever before. If you`re suffering from stabbing pain, ...

This collaboration is based on a press release statement and represents a strategic step in addressing the unmet medical needs for neuropathy treatments in India. In other recent news, Sonnet ...

Data from the SENZA-PDN trial showed 10 kHz SCS yielded long-term, clinically meaningful reductions in HbA1c and weight in patients with PDN and T2D.

Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, ...

With neuropathy, CBD research is even more limited ... CBD oil is relatively new as a treatment for many conditions. Research is limited. But the research that does exist shows a great deal ...

This collaboration is based on a press release statement and represents a strategic step in addressing the unmet medical needs for neuropathy treatments in India. In other recent news, Sonnet ...

Suneeta’s research centers on identifying novel molecular signatures and biomarkers to improve the efficacy of cancer ...

Intracanalicular optic nerve injury is the most common form of traumatic optic neuropathy and is accompanied by a high incidence of canal fracture. For the past 20 years treatment with high-dose ...